Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report

Feb 26, 2008, 00:00 ET from MedPredict

    SCOTTSDALE, Ariz., Feb. 26 /PRNewswire/ -- MedPredict Market Research,
 a global provider of pharmaceutical competitive intelligence and market
 research, has published a new report providing critical strategic insight
 for pharma and biotech companies with a stake in the market for Rheumatoid
 Arthritis (RA) therapies.
     In this report, entitled MedPredict Thought Leader Insight & Analysis:
 Rheumatoid Arthritis Q1 2008, MedPredict's global Thought Leader Panel
 debates tough questions facing drug developers:
-- How should rheumatologists sequence/stack biologicals? What will challenge the anti-TNF paradigm? T-cell? B-cell? Mesenchymal cell? -- How big of a benefit will oral dosing provide in this patient population? Syk? Jak? p38? CCR? Will orals move RA treatment into the community? -- What do they hear from Pharma? What will Wyeth do when they return to Amgen the rights to etanercept? How strong is AstraZeneca's commitment to arthritis? -- Why is it so hard to treat gout? "There continue to be significant unmet needs in this market," says MedPredict President Jeffrey D. Berk. "According to our Panelists, only half of RA patients achieve remission on their first biological therapy and these remissions aren't durable. Even with completely new options many patients are left under-satisfied and demanding better results from their physicians. This report sheds light on these unmet needs and reveals Panelists' views of the most promising candidates." Drugs/Companies mentioned in this report: allopurinol; febuxostat (Teijin/Ipsen/TAP); Puricase (pegloticase; Savient); Remicade (infliximab; Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira (adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab (Amgen); golimumab (Centocor/Schering-Plough/Essex); Actemra (tocilizumab; Roche/Chugai); Cimzia (certolizumab; UCB); GA101 (anti-BR3-Fc/anti-BR3 MAb Biogen/Genentech); LymphoStat-B(R) (belimumab; Human Genome Sciences/GSK); Atacicept (TACI-Ig; ZymoGenetics/Merck-Serono); BMS-582949 (BMS); 856553 (GSK); CP-690550 (Pfizer); INCB18424 (Incyte); tamatinib (R788; Rigel); baminercept (BG9924; Biogen); MLN-3897 (Millennium/Sanofi-Aventis); AZD5672 (AstraZeneca); RWJ-445380 (Alza/J&J); AZD9056 (AstraZeneca); everolimus (RAD-001; Novartis); MM-093 (Merrimack) This report can be purchased by contacting MedPredict. About MedPredict MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict